Sections
Health
Pharma
Biotech
Politics
In the Lab
First Opinion
The Watchdogs
Topics
Biotechnology
Cancer
CRISPR
Drug Development
Drug Pricing
Infectious Disease
Opioids
Pharmaceuticals
Public Health
Trump
Multimedia
The Readout LOUD
Science Happens!
Explainers
Boddities
All Video
Newsletters
More
Most Popular
Industry Event Calendar
STAT Madness
STAT Wunderkinds
Job Board
Log in
Subscribe
Newsletters
Try STAT Plus
Newsletters
Try STAT Plus
The Pharmalot View
By
Ed Silverman
The Pharmalot View
An open letter to Mylan CEO Heather Bresch about EpiPen pricing
By
Ed Silverman
The Pharmalot View
Laws to shed light on drug pricing strategies probably won’t work
By
Ed Silverman
advertisement
The Pharmalot View
Pharma should not be allowed a loophole for reporting financial ties to docs
By
Ed Silverman
advertisement
The Pharmalot View
The ‘gouge factor’: Big companies want transparency in drug price negotiations
By
Ed Silverman
The Pharmalot View
Pharma trade group says price gougers are outliers, but then accepts two more
By
Ed Silverman
The Pharmalot View
Pfizer wins big in opioid deal with Chicago. But what does the city get?
By
Ed Silverman
The Pharmalot View
Independence would be good for the FDA and the public
By
Ed Silverman
advertisement
The Pharmalot View
Drug industry overstates impact of patent reviews on innovation
By
Ed Silverman
advertisement
The Pharmalot View
Novartis, Colombia face off over cancer drug cost
By
Ed Silverman
The Pharmalot View
To get over sticker shock, new payment models are needed for gene therapies
By
Ed Silverman
The Pharmalot View
Cash prizes for pharma are needed to fight superbugs
By
Ed Silverman
The Pharmalot View
Why we shouldn’t trade a weakened FDA for more medical research funds
By
Ed Silverman
The Pharmalot View
Big drug maker presses for money-back guarantee that its science will work
By
Ed Silverman
The Pharmalot View
Who should pay for disposing unused drugs? Pharma says: not us
By
Ed Silverman
The Pharmalot View
Generic drug labels don’t always list known side effects. It’s time to change that
By
Ed Silverman
The Pharmalot View
This nonprofit is playing a valuable role in framing the drug price discussion
By
Ed Silverman
The Pharmalot View
What Valeant’s fall from grace can teach the drug industry
By
Ed Silverman
The Pharmalot View
How much should that drug cost? Depends what disease it treats
By
Ed Silverman
The Pharmalot View
Obama’s Medicare drug payment overhaul is unproven. But it’s worth a shot
By
Ed Silverman
The Pharmalot View
Could financing health care like a home hold down drug costs?
By
Ed Silverman
« Previous Page
Sign up for our Morning Rounds newsletter
Your daily dose of what’s new in health and medicine.
Industry
Please select
Academia
Advertising/Marketing
Advocacy
Biotech
Consultancy/Firm
Financial Services
Government
Healthcare Payer
Healthcare Provider
Media
Medical Device
Non-profit
Pharma
Technology
Leave this field empty if you're human:
X
